ArticleJournal of nanobiotechnology2026
Turmeric-derived exosome-coated ZIF-8 nanoplatform for targeted delivery of TGF-β1 siRNA in the treatment of liver fibrosis.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Iron-Hijacking Trojan Horse Nanoplatform Combats Implant-Associated Biofilm Infections Through Immuno-Fibrotic Remodeling.Advanced materials (Deerfield Beach, Fla.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Liver fibrosis constitutes a progressive pathological condition for which TGF-β1 pathway-targeted siRNA therapy holds considerable therapeutic potential. Nevertheless, clinical application of TGF-β1 siRNA is critically limited by inherent instability and inefficient delivery in vivo. In this study, we engineered an innovative siRNA delivery platform through the integration of turmeric-derived exosome-like nanovesicles (TDEs) with a metal-organic framework (ZIF-8) to generate TDEs@ZIF-8@TGFβ1siRNA nanoparticles, thereby enhancing siRNA delivery efficiency and therapeutic efficacy in liver fibrosis. Characterization revealed TDEs@ZIF-8@TGFβ1siRNA nanoparticles exhibited a well-defined nanostructure with a high TGF-β1 siRNA encapsulation efficiency of 64.73%. Additionally, the system exhibited pH-responsive release and lysosomal escape capabilities, significantly enhancing siRNA stability and cellular uptake efficiency. In vitro, TDEs@ZIF-8@TGFβ1siRNA effectively inhibited hepatic stellate cells (HSCs) activation, reducing TGF-β1, Collagen I, and CTGF mRNA levels by 78.6%, 72.1%, and 69.4%, respectively. In a CCl
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.